Cargando…

Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review

Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic revi...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosamilia, Francesca, Noberasco, Giovanni, Olobardi, Dario, Orsi, Andrea, Icardi, Giancarlo, Lantieri, Francesca, Murdaca, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617735/
https://www.ncbi.nlm.nih.gov/pubmed/34835261
http://dx.doi.org/10.3390/vaccines9111330
_version_ 1784604577650180096
author Rosamilia, Francesca
Noberasco, Giovanni
Olobardi, Dario
Orsi, Andrea
Icardi, Giancarlo
Lantieri, Francesca
Murdaca, Giuseppe
author_facet Rosamilia, Francesca
Noberasco, Giovanni
Olobardi, Dario
Orsi, Andrea
Icardi, Giancarlo
Lantieri, Francesca
Murdaca, Giuseppe
author_sort Rosamilia, Francesca
collection PubMed
description Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients’ category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage.
format Online
Article
Text
id pubmed-8617735
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86177352021-11-27 Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review Rosamilia, Francesca Noberasco, Giovanni Olobardi, Dario Orsi, Andrea Icardi, Giancarlo Lantieri, Francesca Murdaca, Giuseppe Vaccines (Basel) Systematic Review Systemic sclerosis (scleroderma, SSc) is an autoimmune connective tissue disease characterized by excessive production of collagen and multiorgan involvement. Scleroderma patients are at increased risk of influenza complications and pneumonia; thus, vaccinations are recommended. This systematic review evaluated the influenza and pneumococcus vaccination coverage for SSc patients. We included all studies from Pubmed reporting on influenza and pneumococcal vaccination rate in Scleroderma patients up to May 2021. The 14 studies thus selected identified a suboptimal vaccination rate in autoimmune and SSc patients, ranging from 28 to 59% for the flu vaccine, and from 11 to 58% for the pneumo vaccine in absence of specific vaccination campaigns, variously considering also other variables such as age, gender, vaccination settings, and possible vaccination campaigns. We also considered the reasons for low coverage and the approaches that might increase the vaccination rates. A lack of knowledge about the importance of vaccination in these patients and their doctors underlined the need to increase the awareness for vaccination in this patients’ category. Current guidelines recommend vaccination in elderly people and people affected by particular conditions that widely overlap with SSc, yet autoimmune diseases are not always clearly mentioned. Improving this suboptimal vaccination rate with clear guidelines is crucial for SSc patients and for clinicians to immunize these categories based principally on the pathology, prior to the age. Recommendations by the immunologist and the direct link to the vaccine providers can highly improve the vaccine coverage. MDPI 2021-11-15 /pmc/articles/PMC8617735/ /pubmed/34835261 http://dx.doi.org/10.3390/vaccines9111330 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Systematic Review
Rosamilia, Francesca
Noberasco, Giovanni
Olobardi, Dario
Orsi, Andrea
Icardi, Giancarlo
Lantieri, Francesca
Murdaca, Giuseppe
Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_full Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_fullStr Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_full_unstemmed Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_short Flu and Pneumococcal Vaccine Coverage in Scleroderma Patients Still Need to Be Prompted: A Systematic Review
title_sort flu and pneumococcal vaccine coverage in scleroderma patients still need to be prompted: a systematic review
topic Systematic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8617735/
https://www.ncbi.nlm.nih.gov/pubmed/34835261
http://dx.doi.org/10.3390/vaccines9111330
work_keys_str_mv AT rosamiliafrancesca fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview
AT noberascogiovanni fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview
AT olobardidario fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview
AT orsiandrea fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview
AT icardigiancarlo fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview
AT lantierifrancesca fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview
AT murdacagiuseppe fluandpneumococcalvaccinecoverageinsclerodermapatientsstillneedtobepromptedasystematicreview